Clinical Pharmacokinetics of Heparin

1980 ◽  
Vol 14 (7-8) ◽  
pp. 483-488
Author(s):  
Ralph H. Raasch

The pharmacokinetic literature regarding heparin is reviewed, and suggestions regarding the therapeutic use of this anticoagulant are provided. Various kinetic parameters for heparin have been reported, including half-life of pharmacological (anticoagulant) effects using in vitro clotting time tests, and half-life and clearance of heparin using assays of heparin activity. Heparin half-life is shorter, and clearance is greater, in patients with pulmonary emboli compared to patients with deep venous thrombosis. However, heparin infusion rates may be similar regardless of type of thromboembolic disease to achieve a given pharmacological endpoint. The difference in in vitro clotting time test responses among patients given similar amounts of heparin is a most significant variable in determining heparin dosing regimens, and makes continued monitoring of heparin dosage and the associated in vitro clotting time test response necessary for the rational use of this drug.

1969 ◽  
Vol 21 (03) ◽  
pp. 516-523
Author(s):  
H Engelberg ◽  
L. P Engelberg

SummaryThe addition of small amounts of extrinsic thromboplastin or of thrombin to blood in vitro accelerated coagulation more frequently and to a greater extent when determined by the flowing time test than when measured by the silicone clotting time, or by the blood or plasma heparin tolerance tests. Similar results were obtained when intrinsic thromboplastin formation was stimulated by contact with glass. However there was little or no acceleration of the flowing clotting time of plasma obtained from aliquots of the thromboplastin-containing blood. These results indicate that the flowing clotting time (thrombus formation time) of whole blcod is a more reliable test of hypercoagulability than previously described blood or plasma clotting time tests.


1985 ◽  
Vol 53 (02) ◽  
pp. 278-281 ◽  
Author(s):  
H Asbjørn Holm ◽  
Ulrich Abildgaard ◽  
Sigmund Kalvenes

SummaryBleeding complications occurred in 30 (11%) out of 280 patients who received continuous heparin infusion for deep venous thrombosis (DVT). 22 (8%) had minor while 8 patients (3%) had major bleeding complications (1 intrathoracic [fatal], 2 gastrointestinal and 5 retroperitoneal). Heparin activity, in daily drawn blood samples, was determined by four assays (chromogenic substrate [CS] assay, activated partial thromboplastin time [APTT], thrombin time with citrated plasma [CiTT] and thrombin time with recalcified plasma [CaTT]). The differences in median heparin activity between patients with minor bleeding and patients with no bleeding did not reach significance for any of the tests. In patients with major bleeding, the differences were significant with the CS (p = .011) and the CaTT (p = .030) assays. Patients with retroperitoneal bleeding had significantly increased median activity judged by all four assays: CS (p = .002), CaTT (p = .003), APTT (p = .010), CiTT (p = .029). The difference was most pronounced after four days of heparin treatment, but there was a considerable overlap with patients without bleeding.


2007 ◽  
Vol 342-343 ◽  
pp. 605-608 ◽  
Author(s):  
Yi Bin Ren ◽  
Hua Juan Yang ◽  
Ke Yang ◽  
Bing Chun Zhang

The in vitro blood compatibility of a new nickel free high nitrogen austenitic stainless steel Fe-Cr-Mn-Mo-N (BIOSSN4) was studied by the kinetic clotting time test and the platelet rich plasma adhesion test in this paper. In comparison with 316L stainless steel, the kinetic clotting time of BIOSSN4 steel are longer, and only causes less activation of platelets in platelet adhesion test, which was indicated by their morphology and low spreading. The experimental results reveals that the BIOSSN4 stainless steel has better blood compatibility, the blood compatibility mechanism of steels was analyzed based on surface tension and interfacial tension between the steels and blood.


2004 ◽  
Vol 48 (11) ◽  
pp. 4195-4199 ◽  
Author(s):  
Khalid H. Ibrahim ◽  
Brent W. Gunderson ◽  
Elizabeth D. Hermsen ◽  
Laurie B. Hovde ◽  
John C. Rotschafer

ABSTRACT Pulse dosing is a novel approach to dosing that produces escalating antibiotic levels early in the dosing interval followed by a prolonged dose-free period. Antibiotic is frontloaded by means of four sequential bolus injections, after which antibiotic levels are allowed to diminish until the next dose. This study compares standard thrice-daily dosing and pulse dosing of metronidazole against Bacteroides spp. in an in vitro model. Two American Type Culture Collection Bacteroides fragilis isolates (metronidazole MIC for each organism = 1 mg/liter) were exposed to metronidazole for 48 or 96 h. Human pharmacokinetics were simulated for an oral 500-mg dose given every 8 h (maximum concentration of drug [C max] = 12 mg/liter; half-life = 8 h; area under the curve [AUC] = 294 mg · h/liter) and for pulse dosing. Pulses, each producing an increase in metronidazole concentration of 9 mg/liter, were administered at times 0, 2, 4, and 6 h of each 24-h cycle, with a targeted half-life of 8 h (AUC = 347 mg · h/liter). A metronidazole-resistant B. fragilis strain (metronidazole MIC = 32 mg/liter) was exposed to both dosing regimens and, additionally, to a regimen of 1,500 mg administered once daily (C max = 36 mg/liter; AUC = 364 mg · h/liter). Furthermore, regimens against one B. fragilis isolate and one B. thetaiotaomicron isolate corresponding to one-fourth and one-eighth of the thrice-daily and pulse dosing regimens, mimicking peak metronidazole concentrations achieved in abscesses, were simulated in 48-h experiments (metronidazole MIC = 1 mg/liter). Time-kill curves were generated for each experiment and analyzed for bactericidal activity, defined as a bacterial burden reduction ≥ 3 log10 CFU/ml. The results of paired (Wilcoxon matched-pair signed-rank test) and nonpaired (Mann-Whitney test) statistical analyses conducted on time to 3 log10 kill data and area under the kill curve data from each of the thrice-daily dosing experiments versus each of the pulse dosing experiments were considered not significant for a given isolate-dosing regimen combination. The thrice-daily dosing, pulse dosing, and once-daily dosing regimens all exhibited bactericidal activity. Metronidazole administered in standard or pulse dosing fashion was highly active against both susceptible and resistant strains of Bacteroides spp.


Author(s):  
Hui Zhu ◽  
Lei Fu ◽  
Bin Wang ◽  
Xi Chen ◽  
Jiaojie Zhao ◽  
...  

Clofazimine (CFZ) and TBI-166 belong to the riminophenazine class of antimicrobial agent. TBI-166 exhibited promising anti-tuberculosis activity in vitro and in animal models, is currently under phase I clinical development for the treatment of tuberculosis in China. To identify an optimal dosing regimen to support further clinical development of TBI-166, the efficacy of CFZ and TBI-166 were evaluated in two aerosol infection models utilizing BALB/c and C3HeB/FeJNju mice. TBI-166 and CFZ were dosed at 20 mg/kg daily for two weeks, followed by QD (once daily), TIW (thrice weekly) and BIW (twice weekly) for additional 10-weeks at the same dose level. The bactericidal activities of TBI-166 and clofazimine via QD, TIW and BIW dosing regimens were determined after treatment. Once daily administration of CFZ and TBI-166 appeared to be more efficacious than the two intermittent dosing regimens. Once daily administration of TBI-166 increased the bactericidal activity by approximately 1 log10 CFU in the lung and spleen as compared with TIW or BIW dosing after 12 weeks of treatment, while once daily administration of CFZ increased the bactericidal activity by 1.27 to 1.90 log10 CFU/lung and by 1.61 to 2.22 log10 CFU/spleen in BALB/c mouse model, as compared to the intermittent therapies. The difference between QD and TIW and between QD and BIW were significant (P<0.05). The data suggest that accumulated total doses are correlated to the log10 CFU reductions. Therefore intermittent administration of TBI-166 and CFZ should be further evaluated at the same accumulated total doses in preclinical and clinical studies.


1998 ◽  
Vol 42 (3) ◽  
pp. 659-665 ◽  
Author(s):  
Alexander A. Firsov ◽  
Alexander A. Shevchenko ◽  
Sergey N. Vostrov ◽  
Stephen H. Zinner

ABSTRACT Earlier efforts to search for pharmacokinetic and bacteriological predictors of fluoroquinolone antimicrobial effects (AMEs) have resulted in conflicting findings. To elucidate whether these conflicts are real or apparent, several predictors of the AMEs of two pharmacokinetically different antibiotics, trovafloxacin (TRO) and ciprofloxacin (CIP), as well as different dosing regimens of CIP were examined. The AMEs of TRO given once daily (q.d.) and CIP given q.d. and twice daily (b.i.d.) against Escherichia coli,Pseudomonas aeruginosa, and Klebsiella pneumoniae were studied in an in vitro dynamic model. Different monoexponential pharmacokinetic profiles were simulated with a TRO half-life of 9.2 h and a CIP half-life of 4.0 h to provide similar eightfold ranges of the area under the concentration-time curve (AUC)-to-MIC ratios, from 54 to 432 and from 59 to 473 (μg · h/ml)/(μg/ml), respectively. In each case the observation periods were designed to incorporate full-term regrowth phases in the time-kill curves, and the AME was expressed by its intensity (IE ; the area between the control growth and time-kill and regrowth curves up to the point at which the viable counts of regrowing bacteria are close to the maximum values observed without drug). Species-independent linear relationships were established between IE and log AUC/MIC, log AUC above MIC (log AUCeff), and time above the MIC (T eff). Specific and nonsuperimposedIE versus log AUC/MIC or log AUCeffrelationships were inherent in each of the treatments: TRO given q.d. (r 2 = 0.97 and 0.96), CIP given q.d. (r 2 = 0.98 and 0.96), and CIP given b.i.d. (r 2 = 0.95 and 0.93). This suggests that in order to combine data sets obtained with individual quinolones to examine potential predictors, one must be sure that these sets may be combined. Unlike AUC/MIC and AUCeff, the IE -T effrelationships plotted for the different quinolones and dosing regimens were nonspecific and virtually superimposed (r 2 = 0.95). Hence, AUC/MIC, AUCeff, and T eff were equally good predictors of the AME of each of the quinolones and each dosing regimen taken separately, whereas T eff was also a good predictor of the AMEs of the quinolones and their regimens taken together. However, neither the quinolones nor the dosing regimens could be distinguished solely on the basis of T eff, whereas they could be distinguished on the basis of AUC/MIC or AUCeff. Thus, two types of predictors of the quinolone AME may be identified: intraquinolone and/or intraregimen predictors (AUC/MIC, AUCeff and Teff) and an interquinolone and interregimen predictor (T eff). T eff may be able to accurately predict the AME of one quinolone on the basis of the data obtained for another quinolone.


1954 ◽  
Vol 100 (2) ◽  
pp. 135-161 ◽  
Author(s):  
Frank L. Horsfall

Procedures which make possible the enumeration of both infective and hemagglutinating influenza A virus particles have been developed and used in a quantitative investigation on the reproduction of the agent. Infective particles were found to be highly unstable and their half-life was only 147 minutes in allantoic fluid at 35°C. both in vitro and in vivo. The instability of infective particles provides an explanation for the rapid accumulation of non-infective particles which retained the hemagglutinating property. The number of non-infective (N) particles was determined from the difference between the number of hemagglutinating (H) particles and the number of infective (I) particles as indicated by the relation: [N] = [H]– [1]. When the half-life of infective particles was taken into account, both infective and hemagglutinating particles were found to disappear from the allantoic fluid; i.e., were adsorbed by the allantoic membrane, at the same logarithmic rate after inoculation. Inoculation of any number of particles up to 3 x 107 was followed by a constant and progressive decrease in the proportion of unadsorbed particles from 0 to 4 hours. Approximately 20 per cent of particles were unadsorbed at 2 hours and about 5 per cent at 4 hours. Inoculation of 3 x 108 or more particles led to a larger proportion of unadsorbed particles at 4 hours. The maximum number of particles adsorbed was computed to be about 1.6 x 109. The concentration of both infective and hemagglutinating particles increased rapidly in the allantoic fluid after 4 hours when any number of infective particles up to 3 x 107 was inoculated. With such inocula, the rate of increase during the logarithmic period was constant and the time to double the concentration of infective or hemagglutinating particles was 46 minutes. With larger inocula, i.e. 3 x 108 particles, the concentrations of infective and hemagglutinating particles did not increase until after 8 hours and the rate of increase was much slower. The time to double the concentration of either then became 92 minutes. The number of infective particles was approximately equal to the number of hemagglutinating particles during the logarithmic increase period when any number of infective particles up to 3 x 106 was inoculated and no more than 106 non-infective particles were included in the inoculum. This finding was taken to indicate that all or almost all particles produced and released under these conditions were infective. That such particles became inactivated rapidly and led to the accumulation of an increasing number of non-infective particles after the logarithmic period can be explained by the short half-life of infective particles. The number of infective particles was no larger than one-tenth the number of hemagglutinating particles during the logarithmic increase period after 3 x 107 or more infective particles had been inoculated or when smaller inocula were used which also contained 3 x 107 or more non-infective particles. Non-infective particles prepared in vitro at 35° or 22°C. were as effective as those which accumulated in vivo in diminishing the proportion of infective particles in the yield. The extent of the reduction in the proportion of infective particles was directly related to the number of non-infective particles included in the inoculum. The yield of hemagglutinating particles was diminished when the inoculum contained 3 x 107 or more non-infective particles. The rate of increase was reduced so that the time to double the concentration became 92 minutes when the inoculum contained 3 x 108 non-infective particles. It appears from these findings that the single condition which will lead to the emergence of non-infective particles during the logarithmic period is a high initial particle-cell ratio. Because non-infective particles are equally as effective as infective particles in producing this result, it seems probable that the appearance of non-infective but hemagglutinating particles is not a necessary accompaniment of the reproductive process.


1979 ◽  
Vol 42 (04) ◽  
pp. 1276-1285 ◽  
Author(s):  
Javier Pizzuto ◽  
Sergio Garcìa-Méndez ◽  
Marìa de-la-Paz Reyna ◽  
Manuel R Morales ◽  
Agustìn Avilés ◽  
...  

SummaryA modification of the thrombin time test (TT), which permits quantitative measurement of plasma heparin activity during therapy is described. The prolonged TT of plasma containing heparin can be corrected by dilution with platelet-rich plasma (PRP). Clinical heparin activity is considered adequate when prolonged TT of the plasma can be corrected at dilutions of from 1:4 to 1:8 (±20%). In vitro studies of 30 PRP samples containing different amounts of heparin showed that 1:4 and 1:8 dilutions did not correct prolonged TT (P<0.05) in the presence of more than 0.2 and 0.3 U of heparin/ml respectively, indicating that the adequate dose of heparin should fall between those levels which show correction at these dilutions, using the diluted TT method.Patients treated with 100 U of heparin/kg every 4 or 6 h were studied: 52 without previous coagulation defects and 22 with disseminated intravascular coagulation (DIC). The results in the first group showed adequate dosage in 29 cases, overdosage in 12 and underdosage in 11. Hemorrhage occurred in 5 of the overdosage group. In the DIC series, 4 with underdosage of heparin did not improve; in 13 of 18 with adequate dosage, both hemorrhage and coagulapathy disappeared, while the other 5, with more severe complications did not improve. Based on these findings, the diluted TT appears to be a useful test in the assessment of heparin therapy, even in patients with previous coagulation abnormalities.


1977 ◽  
Vol 16 (04) ◽  
pp. 157-162 ◽  
Author(s):  
C. Schümichen ◽  
B. Mackenbrock ◽  
G. Hoffmann

SummaryThe bone-seeking 99mTc-Sn-pyrophosphate compound (compound A) was diluted both in vitro and in vivo and proved to be unstable both in vitro and in vivo. However, stability was much better in vivo than in vitro and thus the in vitro stability of compound A after dilution in various mediums could be followed up by a consecutive evaluation of the in vivo distribution in the rat. After dilution in neutral normal saline compound A is metastable and after a short half-life it is transformed into the other 99mTc-Sn-pyrophosphate compound A is metastable and after a short half-life in bone but in the kidneys. After dilution in normal saline of low pH and in buffering solutions the stability of compound A is increased. In human plasma compound A is relatively stable but not in plasma water. When compound B is formed in a buffering solution, uptake in the kidneys and excretion in urine is lowered and blood concentration increased.It is assumed that the association of protons to compound A will increase its stability at low concentrations while that to compound B will lead to a strong protein bond in plasma. It is concluded that compound A will not be stable in vivo because of a lack of stability in the extravascular space, and that the protein bond in plasma will be a measure of its in vivo stability.


2010 ◽  
Vol 30 (04) ◽  
pp. 212-216 ◽  
Author(s):  
R. Jovic ◽  
M. Hollenstein ◽  
P. Degiacomi ◽  
M. Gautschi ◽  
A. Ferrández ◽  
...  

SummaryThe activated partial thromboplastin time test (aPTT) represents one of the most commonly used diagnostic tools in order to monitor patients undergoing heparin therapy. Expression of aPTT coagulation time in seconds represents common practice in order to evaluate the integrity of the coagulation cascade. The prolongation of the aPTT thus can indicate whether or not the heparin level is likely to be within therapeutic range. Unfortunately aPTT results are highly variable depending on patient properties, manufacturer, different reagents and instruments among others but most importantly aPTT’s dose response curve to heparin often lacks linearity. Furthermore, aPTT assays are insensitive to drugs such as, for example, low molecular weight heparin (LMWH) and direct factor Xa (FXa) inhibitors among others. On the other hand, the protrombinase-induced clotting time assay (PiCT®) has been show to be a reliable functional assay sensitive to all heparinoids as well as direct thrombin inhibitors (DTIs). So far, the commercially available PiCT assay (Pefakit®-PiCT®, DSM Nutritional Products Ltd. Branch Pentapharm, Basel, Switzerland) is designed to express results in terms of units with the help of specific calibrators, while aPTT results are most commonly expressed as coagulation time in seconds. In this report, we describe the results of a pilot study indicating that the Pefakit PiCT UC assay is superior to the aPTT for the efficient monitoring of patients undergoing UFH therapy; it is also suitable to determine and quantitate the effect of LMWH therapy. This indicates a distinct benefit when using this new approach over the use of aPPT for heparin monitoring.


Sign in / Sign up

Export Citation Format

Share Document